Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation

• Status: Active, not recruiting
• Trial end date: 2023-09-13
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to evaluate the efficacy of different lines of therapies on the TWEAK serum level in patients with non-segmental vitiligo.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Shaimaa Fawzy Abdel-rady Abdel-latif
• Treatments: Latanoprost

Criteria

Inclusion Criteria:

• Patients with non-segmental vitiligo of any age and gender.

Exclusion Criteria:

• History of vitiligo treatment with topical, systemic or biological agents prior to the study for at least 3 weeks.

• Pregnancy and lactation.

• Infections

• Patients with other autoimmune diseases.

• Patients with chronic diseases: cardiac diseases, hepatic disorders, hematologic disease, chronic renal failure or malignancies.